Mission

Acute Kidney Injury (AKI) causes 1.7 million deaths per year globally. AKI is a frequent, clinical event occurring in up to 20% of all hospital patients. It is characterized by a rapid deterioration of renal function to varying degrees, and associated with an up to 15-fold higher risk of death. Patients with AKI have a significantly higher risk of developing chronic kidney disease.

Nephrolyx’s mission is to provide all diagnostic tools necessary to rapidly and precisely measure kidney function to enable earlier and more confident detection of AKI.

Vision

Nephrolyx IVD^× will be the standard test for every patient in every ICU worldwide to measure kidney function and detect AKI before it causes severe harm or death.

About Nephrolyx IVD^×

The standard of care for AKI detection in clinical routine is based on a biomarker measurement and takes 48 to 72 hours to yield results, thus leading to delayed therapeutic intervention. Translating the scientific expertise in kidney function measurement into clinical routine, Nephrolyx utilizes a database, a protocol for contrast agent measurement, and a proprietary software to diagnose AKI within the first two to seven hours – less than one tenth of the standard timeline. Nephrolyx is easy to integrate into today’s clinical workflow everywhere and, given low component costs, promises a step-changing improvement in both patient outcomes and healthcare system performance.